Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Nov 8, 2018 • 8:00 AM EST
Ligand Reports Third Quarter 2018 Financial Results
Nov 2, 2018 • 9:00 AM EDT
Ligand to Participate in Stephens NY Investment Conference
Oct 15, 2018 • 9:00 AM EDT
Ligand to Report Third Quarter 2018 Results on November 8th
Nov 8, 2018 • 9:00am EST
See all events
Nov 7, 2018 • 1:00pm EST
New York, NY
Sep 5, 2018 • 12:30pm EST
St. Regis Hotel, New York, NY
FDA approves #Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication https://t.co/e5IkjqhalW
Sermonix Pharmaceuticals to present 3 posters at the 2018 San Antonio Breast Cancer Symposium focused on the potent… https://t.co/3sAFc9m1Uq
Viking Therapeutics Presents Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Diseas… https://t.co/5sLN1N3Qmy